NATIONAL INSTITUTES OF HEALTH
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
- Conditions
- Low Grade GliomaRecurrent Childhood Central Nervous System NeoplasmRecurrent NeuroblastomaRefractory GliomaRefractory Primary Central Nervous System NeoplasmAdvanced Malignant Solid NeoplasmRecurrent Childhood EpendymomaRecurrent Childhood Non-Hodgkin LymphomaRecurrent Childhood Soft Tissue SarcomaRecurrent Langerhans Cell Histiocytosis
- Interventions
- First Posted Date
- 2017-07-28
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6
- Registration Number
- NCT03233204
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
- Conditions
- Biphasic MesotheliomaEpithelioid MesotheliomaStage I Pleural Malignant Mesothelioma AJCC v7Stage IA Pleural Malignant Mesothelioma AJCC v7Stage IB Pleural Malignant Mesothelioma AJCC v7Stage II Pleural Malignant Mesothelioma AJCC v7Stage III Pleural Malignant Mesothelioma AJCC v7
- Interventions
- Procedure: Extrapleural PneumonectomyProcedure: PleurectomyRadiation: Radiation Therapy
- First Posted Date
- 2017-07-25
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT03228537
- Locations
- 🇺🇸
Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, Arkansas, United States
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
- Conditions
- Diffuse Large B Cell LymphomaLymphomaNon-Hodgkin's LymphomaLeukemiaAcute Lymphoblastic Leukemia
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 120
- Registration Number
- NCT03226704
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
- Conditions
- Esophageal NeoplasmsSquamous Cell CarcinomaEsophageal CancerEsophageal Squamous Cell CancerEsophageal Adenocarcinoma
- Interventions
- Other: ChemoradiotherapyProcedure: Esophagectomy
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2018-10-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT03223662
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- Conditions
- Diffuse Large B-Cell LymphomaBurkitt LymphomaLymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 145
- Registration Number
- NCT03223610
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
- Conditions
- Ann Arbor Stage III Childhood Non-Hodgkin LymphomaEwing SarcomaAdvanced Malignant Solid NeoplasmEpendymomaHepatoblastomaMalignant GliomaOsteosarcomaPeripheral Primitive Neuroectodermal TumorRecurrent Childhood Central Nervous System NeoplasmMalignant Germ Cell Tumor
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 4
- Registration Number
- NCT03220035
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
- Conditions
- Mucosal MelanomaOral Cavity Mucosal MelanomaStage II Vulvar Cancer AJCC v7Stage IIIA Vulvar Cancer AJCC v7Stage IIIB Vulvar Cancer AJCC v7Vaginal CarcinomaStage IIIC Vulvar Cancer AJCC v7Stage IVA Oral Cavity Cancer AJCC v6 and v7Esophageal CarcinomaStage III Vulvar Cancer AJCC v7
- Interventions
- Procedure: Conventional SurgeryBiological: IpilimumabOther: Laboratory Biomarker AnalysisBiological: NivolumabRadiation: Radiation TherapyOther: Patient Observation
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03220009
- Locations
- 🇺🇸
Alliance for Clinical Trials in Oncology, Boston, Massachusetts, United States
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
- Conditions
- AIDS-Related LymphomaAnn Arbor Stage IV Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell Lymphoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological Study
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT03220022
- Locations
- 🇺🇸
University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
🇺🇸Memorial Hospital West, Pembroke Pines, Florida, United States
🇺🇸John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
- Conditions
- Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Stage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Triple-Negative Breast CarcinomaAnatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Prognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyDrug: PI3Kbeta Inhibitor AZD8186
- First Posted Date
- 2017-07-17
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 23
- Registration Number
- NCT03218826
- Locations
- 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
- Conditions
- Resectable Soft Tissue SarcomaSoft Tissue Sarcoma
- Interventions
- First Posted Date
- 2017-07-14
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT03217266
- Locations
- 🇺🇸
Logan Health Medical Center, Kalispell, Montana, United States
🇺🇸CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States